Cytek Biosciences (CTKB) Treasury Shares (2021 - 2025)

Cytek Biosciences has reported Treasury Shares for 5 years, with the latest figure at $5.1 million in Q2 2025.

• For the quarter ending Q2 2025, Treasury Shares rose 1057.97% year-over-year to $5.1 million; the trailing twelve-month figure through Jun 2025 stood at $5.1 million (up 1057.97% YoY), and the FY2023 full-year result was $6.6 million, up 465.52% from the prior year.
• Treasury Shares for Q2 2025 stood at $5.1 million, down from $9.3 million in the prior quarter.
• The five-year high for Treasury Shares was $9.3 million in Q3 2024, with the low at $104876.0 in Q4 2021.
• Historically, Treasury Shares has averaged $3.0 million across 5 years, with a median of $1.2 million in 2022.
• Annual changes were most pronounced in 2024 — Treasury Shares plunged 85.63% — and 2025, when it surged 1057.97%.
• Cytek Biosciences' Treasury Shares stood at $104876.0 in 2021, then surged by 1015.13% to $1.2 million in 2022, then surged by 465.52% to $6.6 million in 2023, then jumped by 39.9% to $9.3 million in 2024, then plunged by 44.39% to $5.1 million in 2025.
• The last three Treasury Shares figures came in at $5.1 million (Q2 2025), $9.3 million (Q3 2024), and $444319.0 (Q2 2024), per Business Quant data.